Skip to main content
Premium Trial:

Request an Annual Quote

X-Chem, Abilita Form Drug Discovery Partnership

NEW YORK (GenomeWeb) – X-Chem and Abilita Bio announced today that they have partnered to discover novel modulators of G-protein coupled receptors (GPCR) and ion channel targets.

Under the terms of the deal, Abilita will generate enabled membrane proteins (EMPs) using a proprietary cell-based directed evolution system — which is designed to optimize key membrane protein properties and retain native structure and pharmacology — for several undisclosed GPCR and ion channel targets. X-Chem will then use its DNA-encoded small molecule libraries — which contain more than 120 billion compounds — to screen the EMPs and identify agonists and/or antagonists against the targets.

The companies will select promising drug leads for further development and commercialization. Additional terms were not disclosed.

"GPCRs and ion channels have always been very challenging targets for target-based screening technologies," X-Chem President and CEO Rick Wagner said in a statement. "Abilita's EMP platform, coupled with X-Chem's small molecule discovery engine, opens the gate to the identification of drug leads against hundreds of previously inaccessible targets."

Earlier this year, X-Chem and its collaborators were awarded a $10 million grant from the US Department of Defense to to identify new drug targets for tuberculosis using the company's  DNA-encoded small molecule libraries.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.